Published in PLoS One on August 31, 2012
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. J Med Chem (2014) 1.05
Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacol Res (2014) 0.91
Activity-Based Probe for N-Acylethanolamine Acid Amidase. ACS Chem Biol (2015) 0.80
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants. Curr Neuropharmacol (2015) 0.75
Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol (1999) 33.07
Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem (1962) 7.31
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature (1995) 3.30
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol (2009) 2.82
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol (2007) 2.08
Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem (2005) 1.83
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A (2009) 1.64
Structural comparison of Ntn-hydrolases. Protein Sci (2000) 1.55
Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci U S A (2008) 1.41
The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers (2007) 1.31
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Receptors for acylethanolamides-GPR55 and GPR119. Prostaglandins Other Lipid Mediat (2009) 1.23
Purification, characterization, and biosynthesis of human acid ceramidase. J Biol Chem (1995) 1.23
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol (2008) 1.18
Conjugated bile acid hydrolase is a tetrameric N-terminal thiol hydrolase with specific recognition of its cholyl but not of its tauryl product. Biochemistry (2005) 1.12
Autoproteolytic cleavage and activation of human acid ceramidase. J Biol Chem (2008) 1.10
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. J Med Chem (2005) 1.08
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. J Proteome Res (2008) 1.06
Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol (2007) 0.98
Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J Med Chem (2010) 0.97
A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci (1995) 0.95
A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening. Anal Biochem (2005) 0.95
Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. Bioorg Med Chem Lett (2009) 0.94
Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. Chem Biodivers (2007) 0.92
Proteolytic activation and glycosylation of N-acylethanolamine-hydrolyzing acid amidase, a lysosomal enzyme involved in the endocannabinoid metabolism. Biochim Biophys Acta (2007) 0.91
β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. ACS Med Chem Lett (2012) 0.91
Amino acid residues crucial in pH regulation and proteolytic activation of N-acylethanolamine-hydrolyzing acid amidase. Biochim Biophys Acta (2008) 0.91
Dual modes of modification of hepatitis A virus 3C protease by a serine-derived beta-lactone: selective crystallization and formation of a functional catalytic triad in the active site. J Mol Biol (2005) 0.91
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations. PLoS One (2012) 0.88
Fatty acid amide hydrolase: from characterization to therapeutics. Chem Biodivers (2007) 0.88
Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology. Neurotherapeutics (2012) 0.87
The role of endocannabinoids in pain modulation and the therapeutic potential of inhibiting their enzymatic degradation. Curr Pharm Biotechnol (2011) 0.87
Mass spectrometric characterization of human N-acylethanolamine-hydrolyzing acid amidase. J Proteome Res (2012) 0.83
Beta-lactones as a new class of cysteine proteinase inhibitors: inhibition of hepatitis A virus 3C proteinase by N-Cbz-serine beta-lactone. Org Lett (1999) 0.83
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs (2009) 1.42
CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol (2003) 1.39
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis (2009) 1.35
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci (2008) 1.30
Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats. Behav Pharmacol (2011) 1.27
Cannabinergic ligands. Chem Phys Lipids (2002) 1.25
Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat (2009) 1.25
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol (2008) 1.22
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2003) 1.20
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem (2007) 1.19
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol (2008) 1.18
Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol (2004) 1.16
Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats. Psychopharmacology (Berl) (2005) 1.16
A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.15
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Cannabinoid receptors as therapeutic targets. Curr Pharm Des (2006) 1.13
Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav (2007) 1.13
Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. Anal Chem (2007) 1.13
Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids (2002) 1.12
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther (2008) 1.10
Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology (2005) 1.09
Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem (2005) 1.09
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. J Med Chem (2005) 1.08
Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res (2010) 1.08
CB1 cannabinoid receptor ligands. Mini Rev Med Chem (2005) 1.06
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. J Proteome Res (2008) 1.06
Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev (2002) 1.06
Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med (2008) 1.06
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05
The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J Biol Chem (2005) 1.05
Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacol Biochem Behav (2005) 1.04
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol (2010) 1.04
Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem (2010) 1.03
Cannabinoids inhibit HIV-1 Gp120-mediated insults in brain microvascular endothelial cells. J Immunol (2008) 1.02
Discriminative stimulus functions of methanandamide and delta(9)-THC in rats: tests with aminoalkylindoles (WIN55,212-2 and AM678) and ethanol. Psychopharmacology (Berl) (2009) 1.02
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci (2009) 1.01
Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J Med Chem (2003) 1.01
Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav (2006) 1.01
Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci (2005) 1.00
Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One (2007) 0.99
C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. J Med Chem (2007) 0.99
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain (2012) 0.99
Incorporating dynamics in E. coli dihydrofolate reductase enhances structure-based drug discovery. J Chem Inf Model (2007) 0.98
Synthesis and characterization of 2-substituted bornane pharmacophores for novel cannabinergic ligands. Tetrahedron Lett (2008) 0.98
Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor. J Proteome Res (2007) 0.98
The conformation of the cytoplasmic helix 8 of the CB1 cannabinoid receptor using NMR and circular dichroism. Biochim Biophys Acta (2005) 0.97
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem (2003) 0.97
Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther (2007) 0.97
Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. J Pharmacol Exp Ther (2013) 0.97
Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. Int Rev Psychiatry (2009) 0.96
Methamphetamine discrimination and in vivo microdialysis in squirrel monkeys. Psychopharmacology (Berl) (2004) 0.96
Heteroadamantyl cannabinoids. J Med Chem (2010) 0.96
(R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A. Eur J Pharmacol (2003) 0.95
From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther (2002) 0.95
Bifunctional agents for reperfusion arrhythmias: novel hybrid vitamin E/class I antiarrhythmics. Bioorg Med Chem (2003) 0.95
Endocannabinoid metabolomics: a novel liquid chromatography-mass spectrometry reagent for fatty acid analysis. AAPS J (2006) 0.95
Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther (2008) 0.94
Drug discrimination in methamphetamine-trained monkeys: effects of monoamine transporter inhibitors. J Pharmacol Exp Ther (2004) 0.94
Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol (2012) 0.94
The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med (2005) 0.93
3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. J Med Chem (2006) 0.93
Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols. Bioorg Med Chem Lett (2002) 0.93
The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats. Pharmacol Biochem Behav (2003) 0.93
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav (2011) 0.93
Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire. Protein Sci (2013) 0.92
Conformationally constrained analogues of 2-arachidonoylglycerol. Bioorg Med Chem Lett (2007) 0.92
The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol (2014) 0.92
The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model. AAPS J (2004) 0.92
Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356). Psychopharmacology (Berl) (2006) 0.92
The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav (2010) 0.90
Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids. Chemistry (2010) 0.90
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav (2012) 0.90
The cannabinergic system as a target for anti-inflammatory therapies. Curr Top Med Chem (2006) 0.89
Diuretic effects of cannabinoids. J Pharmacol Exp Ther (2012) 0.89
Antileishmanial ring-substituted ether phospholipids. J Med Chem (2003) 0.89
Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun (2002) 0.89
Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. Eur J Pharmacol (2005) 0.89
Novel adamantyl cannabinoids as CB1 receptor probes. J Med Chem (2013) 0.88